Chongqing PSK-Health Sci-tech Development Co., Ltd

What Chongqing PSK-Health Sci-tech Development Co., Ltd does

Chongqing PSK-Health Sci-tech Development Co., Ltd (PSK-Health) is a privately held Chinese high-tech joint venture founded in 2004 and headquartered in Chongqing, specializing in the research, manufacture, and distribution of Enhanced External Counterpulsation (EECP/ECP) non-invasive medical therapy systems. The company's core technology uses sequential pneumatic cuffs applied to the lower extremities to augment diastolic blood flow and reduce systolic afterload, providing cardiac and systemic circulatory benefits. Its product portfolio spans the P-ECP/TI portable home-use model, the P-ECP/TM mobile clinical model, and the Lumenair all-in-one system produced through a joint venture with Vaso, with application-specific configurations addressing heart disease, cerebrovascular disease, ischemic ear disease, ischemic optic neuropathy, and erectile dysfunction. PSK-Health holds ISO 13485, CFDA, US FDA, CE, and MDSAP certifications and describes itself as the only ECP manufacturer to have simultaneously obtained CFDA, US FDA, and CE certification.

PSK-Health operates a direct B2B enterprise sales model selling capital equipment to hospitals, cardiac rehabilitation centers, specialty clinics, and home healthcare buyers across more than 20 countries and 30 Chinese provinces, supported by international trade teams, on-site installation, commissioning, and after-sales services. Go-to-market is heavily event-driven, with active participation in CMEF, MEDICA Germany, NHAM Congress Malaysia, ASMIHA Indonesia, and the Great Wall Congress of Cardiology, complemented by a multilingual website presence in 40+ languages. Pricing is quote-based on multi-year contracts. Recent strategic activity has emphasized regulatory consolidation (MDSAP certification in May 2025), Southeast Asian and European geographic expansion, an academic research collaboration with the First Affiliated Hospital of Chongqing Medical University on AI-assisted diagnostic imaging (LSTM + Transformer hybrid model, AUC 0.982), and recognition including the 2024 Guangdong Provincial Science and Technology Award and a Grade A recommendation in the 2025 Chinese Experts' Recommendations on EECP for Ischemic Cerebrovascular Disease.

Name

Chongqing PSK-Health Sci-tech Development Co., Ltd

Legal name

Chongqing PSK-Health Sci-Tech Development Co., Ltd

Website

https://cneecp.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Chongqing PSK-Health Sci-tech Development Co., Ltd is a privately held Chinese medical device manufacturer founded in 2004 that designs, produces, and globally distributes non-invasive EECP/ECP external counterpulsation systems for cardiac rehabilitation and ischemic disease treatment, selling directly to hospitals, clinics, and home healthcare buyers across 20+ countries.

Ownership category

akta.pro rank

Product category

Cardiac Rehabilitation Medical Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• External counterpulsation therapy
• Cardiac rehabilitation equipment
• EECP medical devices
• Cardiopulmonary rehabilitation systems
• Ischemic disease treatment equipment

Headquarters

HQ city

Chongqing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Equipment Sales: Direct sales of EECP/ECP medical devices and systems to hospitals, clinics, and healthcare facilities globally. Revenue generated from equipment sales with associated installation, commissioning, and after-sales service support.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Chongqing PSK-Health Sci-tech Development Co., Ltd manufactures and distributes Enhanced External Counterpulsation (EECP/ECP) therapy systems, which are non-invasive pneumatic medical devices used for cardiac rehabilitation and treatment of ischemic conditions. The company's products include portable, mobile, and all-in-one EECP systems (P-ECP/TI, P-ECP/TM, Lumenair) applied across cardiovascular, cerebrovascular, ENT, ophthalmology, and urological therapeutic areas, sold to hospitals and clinics worldwide.

Product overview

Chongqing PSK-Health Sci-Tech Development Co., Ltd (PSK-Health) is a high-tech joint-venture medical equipment manufacturer established in 2004, specializing in the research, development, manufacture, and distribution of EECP/ECP (Enhanced External Counterpulsation) therapy systems. The company offers a portfolio of non-invasive cardiac rehabilitation equipment including the P-ECP/TI (portable home-use model), P-ECP/TM (mobile model), and Lumenair (all-in-one joint venture system). PSK-Health's EECP products address multiple therapeutic areas: heart diseases (angina, heart failure, coronary artery disease), cerebrovascular diseases (stroke, ischemic optical neuropathy), ear diseases (sudden deafness, tinnitus), eye diseases (ischemic optic neuropathy), erectile dysfunction, and renal ischemic conditions. Products are sold to more than 20 countries and 30 China provinces. The company maintains ISO 13485 quality certification and holds CFDA, US FDA, and CE certifications.

Differentiator

Problem solved

Functional benefit

Products and services

• EECP/ECP for Heart Diseases Non-invasive external counterpulsation therapy device for treating heart diseases including angina, heart failure, coronary artery disease, and myocardial ischemia in clinical settings.
• EECP/ECP for Cerebrovascular Diseases External counterpulsation therapy system designed for ischemic cerebrovascular conditions including stroke recovery and cerebrovascular insufficiency in hospitals and rehabilitation centers.
• EECP/ECP for Ear Disease EECP therapy device for treating ischemic ear diseases including sudden deafness and tinnitus symptoms through improved inner ear circulation.
• EECP/ECP for Eye Disease External counterpulsation therapy for ischemic eye conditions including ischemic optic neuropathy and optic atrophy, aimed at improving ocular blood flow.
• EECP/ECP for Erectile Dysfunction Non-invasive therapy device that improves penile blood flow and erectile function through enhanced external counterpulsation for patients with vascular-related erectile dysfunction.
• P-ECP/TI Portable EECP system suitable for home use or small clinics with mobile capabilities, providing cardiac rehabilitation therapy in non-hospital settings.
• P-ECP/TM Mobile EECP machine model designed for flexible deployment across different clinical settings, supporting cardiac rehabilitation and ischemic disease treatment.
• Lumenair All-in-one EECP therapy system manufactured through a joint venture with Vaso, providing comprehensive cardiac rehabilitation in hospital and clinic environments.

Quantifiable outcome

• EECP therapy can reduce angina symptoms, improve left ventricular function, and enhance quality of life in patients with coronary artery disease.
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• First Affiliated Hospital of Chongqing Medical UniversitycoreStrategic or Co-development Partner · 3 April 2026Academic research collaboration for developing advanced diagnostic technologies. Joint study combining dual-tracer sentinel lymph node biopsy with deep learning (LSTM + Transformer hybrid model) for predicting lymph node metastasis in papillary thyroid carcinoma patients. Research achieved AUC of 0.982 and 94.7% accuracy on testing set.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Yuwell Medical: Chinese medical device manufacturer with home-care and clinical product lines across respiratory, sleep, and cardiovascular monitoring. Comparable peer given PSK's pivot toward portable/home EECP and consumer-adjacent channels.
• Mindray: China-based global medical device manufacturer spanning patient monitoring, in-vitro diagnostics, and medical imaging. Comparable in domestic Chinese distribution reach and international regulatory footprint, with adjacent cardiology and patient-monitoring offerings.

Broad incumbents

• Boston Scientific: Major cardiovascular and interventional cardiology device manufacturer. Broad incumbent in cardiac care whose interventional products compete with EECP for angina and ischemic heart disease treatment decision-making.
• Medtronic: Global cardiovascular device incumbent with broad mechanical circulatory support, cardiac surgery, and rehabilitation portfolios. Competes indirectly by offering alternative treatment pathways (e.g., stents, surgery) to EECP patient populations.
• Abbott (Cardiovascular): Leading cardiovascular medical device company across interventional, structural heart, and cardiac rhythm management. Functions as a broad incumbent whose drug-eluting stents and heart failure devices address the same patient conditions PSK's EECP targets.

Direct peers

• Lepu Medical: Chinese cardiovascular medical device manufacturer with broad interventional cardiology and cardiac care portfolio. Direct regional peer operating in the same Chinese hospital channels as PSK-Health.
• Vasomedical: US-based EECP manufacturer and PSK-Health's joint venture partner on the Lumenair platform. Direct competitor in EECP therapy systems with overlapping global distribution and clinical positioning.
• Cardiomedics: Manufacturer of external counterpulsation (ECP) therapy systems. Direct peer in non-invasive mechanical circulatory support devices used for cardiac rehabilitation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chongqing-psk-health-sci-tech-development-co-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chongqing PSK-Health Sci-tech Development Co., Ltd